TY - JOUR
T1 - The effect of muscimol on prolactin secretion in male rats
AU - Meltzer, H. Y.
AU - Simonovic, M.
AU - Fang, V. S.
PY - 1978/12/1
Y1 - 1978/12/1
N2 - In order to further clarify the conflicting reports on the effect of gamma-aminobutyric acid (GABA) on prolactin (PRL) secretion, we have examined the effect of a potent, centrally active GABA receptor agonist, muscimol, on basal and pharmacologically elevated plasma PRL levels in male rats. Intravenous administration of muscimol, in doses from 0.5-5.0 mg/kg, produced no change in resting plasma PRL levels 15 and 30 minutes after its administration. In animals pretreated with alphamethylparatyrosine (100 mg/kg, intraperitoneally), muscimol (0.1-1.0 mg/kg, i.v.) produced significant decreases in plasma PRL concentrations. Muscimol, (5.0 mg/kg, i.p.) also significantly inhibited PRL secretion in rats pretreated with haloperidol (1.0 mg/kg, i.p.). This effect of muscimol is probably due to its ability to activate central GABA receptors.
AB - In order to further clarify the conflicting reports on the effect of gamma-aminobutyric acid (GABA) on prolactin (PRL) secretion, we have examined the effect of a potent, centrally active GABA receptor agonist, muscimol, on basal and pharmacologically elevated plasma PRL levels in male rats. Intravenous administration of muscimol, in doses from 0.5-5.0 mg/kg, produced no change in resting plasma PRL levels 15 and 30 minutes after its administration. In animals pretreated with alphamethylparatyrosine (100 mg/kg, intraperitoneally), muscimol (0.1-1.0 mg/kg, i.v.) produced significant decreases in plasma PRL concentrations. Muscimol, (5.0 mg/kg, i.p.) also significantly inhibited PRL secretion in rats pretreated with haloperidol (1.0 mg/kg, i.p.). This effect of muscimol is probably due to its ability to activate central GABA receptors.
UR - http://www.scopus.com/inward/record.url?scp=0018126528&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0018126528&partnerID=8YFLogxK
M3 - Article
C2 - 212248
AN - SCOPUS:0018126528
SN - 0145-5699
VL - 2
SP - 231
EP - 236
JO - Communications In Psychopharmacology
JF - Communications In Psychopharmacology
IS - 3
ER -